Blog

atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Apr 14 • 3 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been dosed in Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). This Phase 1 open-label study is designed to assess the safety, tolerability, and pharmacokinetic profile of 60mg, 90mg and…

What Can The Industry Learn From Field Trip Health’s Downfall?

Apr 13 • 6 min read

In the 2022– Year in Psychedelics Report, we predicted that 2023 would bring about the downfall of several psychedelic companies that had not been wise with their strategy. It seems that the time has now come. Over the last month, several companies have announced the closure of psychedelic clinics worldwide, and one of the industry’s…

Jeremy Gardner Has Expanded From Crypto To Psychedelics – Podcast Episode #26

Apr 12 • 1 min read

On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Jeremy Gardner. Jeremy is the Founder and Managing Partner of Mystic Ventures. In this episode, Jeremy talks about his interest in psychedelics, his history with cryptocurrencies, and how he sees the future playing out. Subscribe for More Season Three We still…

Filament Health and Pharmala Biotech Announce Release of GMP MDMA Capsules

Apr 11 • 2 min read

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, and PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE:MDMA), a Canadian biotechnology company dedicated to the research and development of clinical-grade LaNeo™ MDMA and novel MDXX compounds, today announced the GMP release of MDMA capsules at the Metro Vancouver facility operated…

Nucleus CEO Publishes “Letter from the Captain,” Summarizes Q1 Progress

Apr 11 • 9 min read

Psychedelic Invest’s parent company, Nucleus Holding, Inc. is slated to close its crowdfunding campaign this month. Over on the campaign page at Wefunder, Nucleus CEO Logan Lenz published an update that summarizes how he sees Nucleus positioned amidst the current psychedelics industry. The contents of the letter are also posted below. Hello, I’m Logan, the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538